PEAR THERAPEUTICS INC (PEAR) Stock Price, Quote, News and Overview
NASDAQ:PEAR - Nasdaq - US7047231052 - Common Stock - Currency: USD
PEAR Quote, Performance and Key Statistics
0.0292
-0.02 (-38.91%)
The current stock price of PEAR is 0.0292 USD. In the past month the price decreased by -86.07%. In the past year, price decreased by -99.38%.
PEAR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 36.13 | 36.66B | ||
| DOCS | DOXIMITY INC-CLASS A | 56.54 | 13.58B | ||
| WAY | WAYSTAR HOLDING CORP | N/A | 7.26B | ||
| CERT | CERTARA INC | 33.77 | 2.12B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.98B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 15.03 | 1.83B | ||
| SDGR | SCHRODINGER INC | N/A | 1.65B | ||
| PHR | PHREESIA INC | N/A | 1.64B | ||
| EVH | EVOLENT HEALTH INC - A | 15.8 | 1.22B | ||
| HSTM | HEALTHSTREAM INC | 50.58 | 999.88M | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 966.46M | ||
| DH | DEFINITIVE HEALTHCARE CORP | 14.47 | 762.50M |
Related stock screener links
About PEAR
Company Profile
Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The company is headquartered in Boston, Massachusetts and currently employs 200 full-time employees. The company went IPO on 2021-02-02. The firm is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases. Its products include reset, reSET-O and Somryst. The firm's reset product is indicated for the treatment of substance use disorder (SUD) related to alcohol, cannabis, cocaine and stimulants, such as monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The firm's Somryst product is the only software-based and guideline-recommended treatment for chronic insomnia. The Company’s pipeline consists of 14 product candidates, including candidates in psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal (GI), oncology, and cardiovascular. The firm focuses on psychiatric and neurologic conditions.
Company Info
PEAR THERAPEUTICS INC
200 State Street, 13Th Floor
Boston MASSACHUSETTS US
Employees: 200
Company Website: https://peartherapeutics.com/
Phone: 16469322774.0
PEAR THERAPEUTICS INC / PEAR FAQ
What is the stock price of PEAR THERAPEUTICS INC today?
The current stock price of PEAR is 0.0292 USD. The price decreased by -38.91% in the last trading session.
What is the ticker symbol for PEAR THERAPEUTICS INC stock?
The exchange symbol of PEAR THERAPEUTICS INC is PEAR and it is listed on the Nasdaq exchange.
On which exchange is PEAR stock listed?
PEAR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PEAR THERAPEUTICS INC stock?
12 analysts have analysed PEAR and the average price target is 5.44 USD. This implies a price increase of 18530.03% is expected in the next year compared to the current price of 0.0292. Check the PEAR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PEAR THERAPEUTICS INC worth?
PEAR THERAPEUTICS INC (PEAR) has a market capitalization of 4.17M USD. This makes PEAR a Nano Cap stock.
How many employees does PEAR THERAPEUTICS INC have?
PEAR THERAPEUTICS INC (PEAR) currently has 200 employees.
What are the support and resistance levels for PEAR THERAPEUTICS INC (PEAR) stock?
PEAR THERAPEUTICS INC (PEAR) has a resistance level at 0.05. Check the full technical report for a detailed analysis of PEAR support and resistance levels.
Is PEAR THERAPEUTICS INC (PEAR) expected to grow?
The Revenue of PEAR THERAPEUTICS INC (PEAR) is expected to grow by 119.68% in the next year. Check the estimates tab for more information on the PEAR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PEAR THERAPEUTICS INC (PEAR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PEAR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PEAR, evaluating the profitability, health, valuation and growth aspects
- PEAR THERAPEUTICS INC (PEAR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PEAR THERAPEUTICS INC (PEAR) Sales and EPS estimates to see what analysts future expectations are.
- PEAR THERAPEUTICS INC (PEAR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PEAR THERAPEUTICS INC (PEAR) Insider and Institutional Ownership to learn about the owners and their transactions.
- PEAR THERAPEUTICS INC (PEAR) Stock Chart to make your own analysis
- PEAR THERAPEUTICS INC (PEAR) Latest news and press-releases to stay up to date.
Does PEAR THERAPEUTICS INC (PEAR) stock pay dividends?
PEAR does not pay a dividend.
When does PEAR THERAPEUTICS INC (PEAR) report earnings?
PEAR THERAPEUTICS INC (PEAR) will report earnings on 2023-05-15.
What is the Price/Earnings (PE) ratio of PEAR THERAPEUTICS INC (PEAR)?
PEAR THERAPEUTICS INC (PEAR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).
PEAR Technical Analysis
PEAR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PEAR. Both the profitability and financial health of PEAR have multiple concerns.
PEAR Financial Highlights
Over the last trailing twelve months PEAR reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 11.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PEAR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to PEAR. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 10% and a revenue growth 119.68% for PEAR